DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Dreyling M, Jurczak W, Jerkeman M. et al.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma.
Lancet 2016;
387: 770-778
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.